Related Articles
An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells
Alterations in three biomarkers (estrogen receptor, progesterone receptor and human epidermal growth factor 2) and the Ki67 index between primary and metastatic breast cancer lesions
Extended trastuzumab therapy improves the survival of HER2‑positive breast cancer patients following surgery and radiotherapy for brain metastases
Estrogen receptor α and β, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast